Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 1
1952 1
1953 1
1955 1
1956 1
1960 1
1965 1
1969 1
1970 1
1972 2
1978 3
1979 3
1980 5
1981 5
1982 3
1983 5
1984 6
1985 7
1986 8
1987 11
1988 9
1989 10
1990 8
1991 5
1992 7
1993 5
1994 8
1995 14
1996 12
1997 11
1998 16
1999 13
2000 13
2001 19
2002 18
2003 19
2004 16
2005 15
2006 20
2007 16
2008 21
2009 17
2010 27
2011 18
2012 10
2013 20
2014 24
2015 31
2016 25
2017 27
2018 30
2019 32
2020 37
2021 33
2022 25
2023 26
2024 36
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

678 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. DiNardo CD, et al. Among authors: esteve j. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. N Engl J Med. 2020. PMID: 32786187 Clinical Trial.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Pratz KW, et al. Among authors: esteve j. Am J Hematol. 2024 Apr;99(4):615-624. doi: 10.1002/ajh.27246. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343151 Clinical Trial.
Novel Tools for Diagnosis and Monitoring of AML.
Guijarro F, Garrote M, Villamor N, Colomer D, Esteve J, López-Guerra M. Guijarro F, et al. Among authors: esteve j. Curr Oncol. 2023 May 23;30(6):5201-5213. doi: 10.3390/curroncol30060395. Curr Oncol. 2023. PMID: 37366878 Free PMC article. Review.
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M. Spyridonidis A, et al. Among authors: esteve j. Bone Marrow Transplant. 2020 Jun;55(6):1114-1125. doi: 10.1038/s41409-020-0803-y. Epub 2020 Jan 29. Bone Marrow Transplant. 2020. PMID: 31996792 Free article.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV. Wang ES, et al. Among authors: esteve j. Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586. Blood. 2022. PMID: 35917453 Free PMC article. Clinical Trial.
All-Optical Electrochemiluminescence.
Zhao Y, Descamps J, Al Hoda Al Bast N, Duque M, Esteve J, Sepulveda B, Loget G, Sojic N. Zhao Y, et al. Among authors: esteve j. J Am Chem Soc. 2023 Aug 9;145(31):17420-17426. doi: 10.1021/jacs.3c05856. Epub 2023 Jul 27. J Am Chem Soc. 2023. PMID: 37498003 Free article.
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ribera JM, García-Calduch O, Ribera J, Montesinos P, Cano-Ferri I, Martínez P, Esteve J, Esteban D, García-Fortes M, Alonso N, González-Campos J, Bermúdez A, Torrent A, Genescà E, Mercadal S, Martínez-Lopez J, García-Sanz R. Ribera JM, et al. Among authors: esteve j. Blood Adv. 2022 Sep 27;6(18):5395-5402. doi: 10.1182/bloodadvances.2022007764. Blood Adv. 2022. PMID: 35675590 Free PMC article.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrebadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado J. Ortíz-Maldonado V, et al. Among authors: esteve j. Mol Ther. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027. Epub 2020 Sep 20. Mol Ther. 2021. PMID: 33010231 Free PMC article. Clinical Trial.
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: esteve j. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
678 results